JP2024538140A5 - - Google Patents

Info

Publication number
JP2024538140A5
JP2024538140A5 JP2024522608A JP2024522608A JP2024538140A5 JP 2024538140 A5 JP2024538140 A5 JP 2024538140A5 JP 2024522608 A JP2024522608 A JP 2024522608A JP 2024522608 A JP2024522608 A JP 2024522608A JP 2024538140 A5 JP2024538140 A5 JP 2024538140A5
Authority
JP
Japan
Prior art keywords
approximately
concentration
pharmaceutical formulation
buffer
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/125017 external-priority patent/WO2023061424A1/en
Publication of JP2024538140A publication Critical patent/JP2024538140A/ja
Publication of JP2024538140A5 publication Critical patent/JP2024538140A5/ja
Pending legal-status Critical Current

Links

JP2024522608A 2021-10-15 2022-10-13 抗ox40モノクローナル抗体を含む医薬製剤 Pending JP2024538140A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/124200 2021-10-15
CN2021124200 2021-10-15
CN2022118065 2022-09-09
CNPCT/CN2022/118065 2022-09-09
PCT/CN2022/125017 WO2023061424A1 (en) 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Publications (2)

Publication Number Publication Date
JP2024538140A JP2024538140A (ja) 2024-10-18
JP2024538140A5 true JP2024538140A5 (cg-RX-API-DMAC7.html) 2025-10-21

Family

ID=85987310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522608A Pending JP2024538140A (ja) 2021-10-15 2022-10-13 抗ox40モノクローナル抗体を含む医薬製剤

Country Status (13)

Country Link
US (1) US20250282882A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538140A (cg-RX-API-DMAC7.html)
KR (1) KR20240109250A (cg-RX-API-DMAC7.html)
CN (1) CN118541166A (cg-RX-API-DMAC7.html)
AU (1) AU2022367611A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235879A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001157A1 (cg-RX-API-DMAC7.html)
IL (1) IL312138A (cg-RX-API-DMAC7.html)
MX (1) MX2024004619A (cg-RX-API-DMAC7.html)
PE (1) PE20241351A1 (cg-RX-API-DMAC7.html)
TW (1) TW202323280A (cg-RX-API-DMAC7.html)
WO (1) WO2023061424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136116A4 (en) * 2020-04-17 2024-06-19 Hutchison Medipharma Limited ANTI-OX40 ANTIBODIES AND USES THEREOF
CN117257936B (zh) * 2023-10-30 2026-05-01 杭州博之锐生物制药有限公司 一种阿达木单抗组合物
WO2025185555A1 (en) * 2024-03-04 2025-09-12 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof
WO2026130530A1 (en) * 2024-12-19 2026-06-25 Akeso Biopharma Co., Ltd. Antibody formulations with reduced aggregation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
ES3014697T3 (en) * 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
TWI726426B (zh) * 2018-09-25 2021-05-01 大陸商信達生物製藥(蘇州)有限公司 包含抗ox40抗體的製劑、其製備方法及其用途
EP3999537A1 (en) * 2019-07-19 2022-05-25 Ichnos Sciences SA Lyophilized antibody formulation
TW202144005A (zh) * 2020-03-25 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ox40抗體醫藥組成物及其用途

Similar Documents

Publication Publication Date Title
US20220175663A1 (en) Stable liquid antibody formulation
TWI728953B (zh) 治療或預防偏頭痛之方法
AU2016204371B2 (en) Lyophilised and aqueous anti-CD40 antibody formulations
KR102553870B1 (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
JP2022532927A5 (cg-RX-API-DMAC7.html)
AU2019262953B2 (en) Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
TW201100100A (en) Pharmaceutical formulation containing improved antibody molecules
JP2025501028A5 (cg-RX-API-DMAC7.html)
TW202220702A (zh) 一種含抗體藥物偶聯物的醫藥組成物及其用途
US20130122013A1 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2023006055A1 (en) Anti-pd-1 antibody pharmaceutical composition and use thereof
JP2025503339A5 (cg-RX-API-DMAC7.html)
JP2025503614A5 (cg-RX-API-DMAC7.html)
JP2024510142A5 (cg-RX-API-DMAC7.html)
JP2024515968A5 (cg-RX-API-DMAC7.html)
CN118382463A (zh) 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途
JP2023502398A5 (cg-RX-API-DMAC7.html)
JP2022519796A5 (cg-RX-API-DMAC7.html)
CN116391041A (zh) 一种含抗结缔组织生长因子抗体的药物组合物
CN111683681A (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
RU2024127270A (ru) Препараты, содержащие биспецифическое антитело против claudin18.2/cd3, способ их получения и применение
CA3097711C (en) Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
RU2024133531A (ru) Стабильные высококонцентрированные составы на основе аргинина, содержащие антитело к pd-1, и способы их применения
RU2024133528A (ru) Стабильные высококонцентрированные составы на основе хлорида натрия, содержащие антитело к pd-1, и способы их применения
RU2025126216A (ru) Фармацевтическая композиция, содержащая pd-1/pvrig/tigit-связывающий белок, и ее медицинское применение